NovoCure (BMV:NVCR N) - Aktienkurs, Nachrichten und Analyse

NVCR N Aktienübersicht

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

Über das Unternehmen

NVCR N grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 7.1%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 5% pro Jahr sinken.

Aktien sind hochgradig illiquide

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

NovoCure Limited Wettbewerber

MeHow Innovative

SZSE:301363

CN¥11.8b

Guangzhou Wondfo BiotechLtd

SZSE:300482

CN¥11.4b

Shanghai MicroPort EP MedTech

SHSE:688351

CN¥10.4b

Embla Medical hf

CPSE:EMBLA

DKK 12.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für NovoCure
Historische Aktienkurse
Aktueller Aktienkurs	US$275.39
52-Wochen-Hoch	US$2,140.47
52-Wochen-Tief	US$275.39
Beta	0.52
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	-86.68%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	NVCR N	MX Medical Equipment	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie NVCR N im Vergleich zur Branche MX Medical Equipment abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie NVCR N im Vergleich zum MX Markt abgeschnitten hat.

Preisvolatilität

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiler Aktienkurs: NVCR N hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von NVCR N im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2000	1,320	Asaf Danziger	www.novocure.com

NovoCure Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von NovoCure im Vergleich zum Marktanteil des Unternehmens?
NVCR N grundlegende Statistiken
Marktanteil	Mex$27.09b
Gewinn(TTM)	-Mex$3.35b
Umsatz(TTM)	Mex$8.56b

3.2x

Kurs-Umsatz-Verhältnis

-8.1x

Kurs-Gewinn-Verhältnis

Ist NVCR N zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NVCR N Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$503.98m
Kosten der Einnahmen	US$124.00m
Bruttogewinn	US$379.98m
Sonstige Ausgaben	US$577.25m
Umsatz	-US$197.27m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.85
Bruttomarge	75.40%
Nettogewinnspanne	-39.14%
Schulden/Eigenkapital-Verhältnis	144.3%

Wie hat sich NVCR N auf lange Sicht entwickelt?

Historische Performance und Vergleiche

NVCR N Aktienübersicht

Belohnungen

Risikoanalyse

NovoCure Limited Wettbewerber

SZSE:301363

CN¥11.8b

SZSE:300482

CN¥11.4b

SHSE:688351

CN¥10.4b

CPSE:EMBLA

DKK 12.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Recent updates

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

NovoCure Limited's Grundlagenzusammenfassung

3.2x

-8.1x

Erträge &amp; Einnahmen

Erträge & Einnahmen